<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:mp ids='MP_0009308'>Adenocarcinoma</z:mp> of the esophagus is frequently associated with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) </plain></SENT>
<SENT sid="1" pm="."><plain>The response of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> to <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy is well described; however, the effect of <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated BE has not been specifically reported </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To determine the response of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated BE to <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Retrospective cohort study </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: A single National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute Comprehensive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Care Center experience </plain></SENT>
<SENT sid="5" pm="."><plain>PATIENTS: The study cohort consisted of 43 patients with stage I to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IVA</z:e> esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> associated with BE who received either neoadjuvant or definitive <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy and underwent either esophagectomy or surveillance at our institution </plain></SENT>
<SENT sid="6" pm="."><plain>MAIN OUTCOME MEASUREMENT: The presence and extent of BE after <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> associated with endoscopically documented pretreatment BE </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: BE persisted after <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy in 93% (40/43) of cases (95% CI, 83%-99%) </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty-seven patients received neoadjuvant <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy before esophagectomy </plain></SENT>
<SENT sid="9" pm="."><plain>Persistent BE was detected in <z:hpo ids='HP_0000001'>all</z:hpo> 27 surgical specimens (100%) </plain></SENT>
<SENT sid="10" pm="."><plain>In 59% (16/27) of the cases, there was complete pathologic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response </plain></SENT>
<SENT sid="11" pm="."><plain>Sixteen patients received definitive <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Persistent pretreatment BE was identified in 88% (14/16) by surveillance endoscopy (95% CI, 60%-98%) </plain></SENT>
<SENT sid="13" pm="."><plain>The mean length of BE before and after <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> was 6.6 cm and 5.8 cm, respectively (P = .38) </plain></SENT>
<SENT sid="14" pm="."><plain>LIMITATIONS: Retrospective design, small sample size, and single-site data collection </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">Chemoradiation</z:e> therapy of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> does not eliminate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated BE, nor does it affect the length of the BE segment </plain></SENT>
</text></document>